Risk factors

ZeroStack faces extreme regulatory, legal, and operational volatility as an early-stage global cannabis and hemp distributor. The business remains highly vulnerable to federal tax penalties under Section 280E and shifting international cannabis laws. Supply chain disruptions, product liabilities, and banking restrictions threaten long-term viability and growth.

Snowflake’s consumption-based revenue and rapid growth make financial performance difficult to forecast.

Aeva relies heavily on its top two customers, who generated 72% of 2024 revenue, and on two key founders.

Ashford Hospitality Trust faces extreme refinancing and interest rate risks with $2.7 billion in property-level debt. The company relies entirely on third-party advisors and managers like Remington Hospitality. Common stock dividends are suspended for 2025.

Risk section is dominated by the pending merger with REalloys and Nasdaq initial listing requirements. Reliance on subscription growth and third-party SaaS technology creates operational vulnerability. Protection of proprietary platform intellectual property and trade secrets is critical for profitability.

Annovis Bio faces substantial going concern doubt due to recurring net losses of $24.6 million in 2024 and limited cash of $10.6 million against $3.9 million in current liabilities.

Clinical development of novel bacteriophage and synthetic phage technology dominates the risk profile.

The company relies heavily on political organization deposits, particularly affiliated with the U.S. Republican Party, creating high seasonality and concentration risks. Operations are concentrated in the Washington, D.C. area, with significant exposure to interest rate fluctuations and uninsured deposits.

Sprinklr faces substantial risks related to revenue growth sustainability, international operations, and strict data privacy regulations across global markets.

Decoy Therapeutics faces primary risks centered on its pending merger with Salarius, including potential cash shortfalls and Nasdaq delisting. The company relies entirely on unproven oncology therapeutics without commercial revenue or funds for clinical trials.

Dollar General faces significant risks centered on low-income customer spending pressure, heavy inventory management, and intense retail competition.

Greenlane faces substantial risks from its heavy reliance on the evolving, regulated cannabis and vaporizer markets. The company struggles with Nasdaq listing compliance, financial debt, and potential supply chain disruptions. Regulatory uncertainties regarding drug paraphernalia laws and banking access threaten core business operations.